The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

By L. Caly, J. Druce, M. Catton, D. Jans, K. Wagstaff. Antiviral Research, 2020

1,960 citations recorded by the source corpus.

Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.

Subfields: Infectious Diseases, Parasitology, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/ed7608398de967b45d570029be88e3a60cd734d9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

  1. Nima Rezaei
  2. Melika Lotfi
  3. Michael R Hamblin

Citations in the corpus